Columbia Labs Slams Investor Suit Over Rejected Drug

Law360, New York (August 12, 2013, 3:55 PM EDT) -- Columbia Laboratories Inc. fired back Friday in New Jersey federal court against consolidated investor claims that the company and its executives inflated its stock by talking up its premature-birth-preventing drug Prochieve despite allegedly knowing regulators would not approve it, saying the claims lack support.  

In a motion to dismiss filed in New Jersey federal court, the Boston-based pharmaceutical company argued that the investors had not sufficiently supported their claims that the company knowingly withheld information that the U.S. Food and Drug Administration was not going...
To view the full article, register now.